Holen Sie sich die Stockscreener-App
0.875
0.93%
-0.0082
Handel nachbörslich:
.92
0.045
+5.14%
Schlusskurs vom Vortag:
$0.8832
Offen:
$0.905
24-Stunden-Volumen:
108.68K
Relative Volume:
0.76
Marktkapitalisierung:
$37.12M
Einnahmen:
$14.92M
Nettoeinkommen (Verlust:
$-86.88M
KGV:
-0.285
EPS:
-3.0699
Netto-Cashflow:
$-82.31M
1W Leistung:
-12.20%
1M Leistung:
-10.24%
6M Leistung:
-37.94%
1J Leistung:
-64.86%
1-Tages-Spanne:
$0.87
$0.91
1-Wochen-Bereich:
$0.86
$1.0105
52-Wochen-Spanne:
$0.80
$3.16
Carisma Therapeutics Inc Stock (CARM) Company Profile
Firmenname
Carisma Therapeutics Inc
Sektor
Branche
Telefon
(267) 491-6422
Adresse
3675 MARKET STREET, PHILADELPHIA
Vergleichen Sie CARM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CARM | 0.875 | 37.12M | 14.92M | -86.88M | -82.31M | -3.0699 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-06 | Eingeleitet | Evercore ISI | Outperform |
| 2023-05-31 | Hochstufung | Jefferies | Hold → Buy |
| 2023-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-14 | Eingeleitet | Robert W. Baird | Outperform |
Carisma Therapeutics Inc Aktie (CARM) Neueste Nachrichten
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024 - PR Newswire
Carisma Therapeutics Reports Q3 2024 Results, Advances Clinical Programs - MSN
Carisma Therapeutics stock a buy at D. Boral Capital, HER2 & platform value in focus - Investing.com India
Carisma Therapeutics and Moderna Unveil Promising Pre-Clinical Data for Anti-GPC3 CAR-M Therapy - MSN
Carisma Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Carisma reports progress in liver cancer therapy development - Investing.com India
Carisma reports progress in liver cancer therapy development By Investing.com - Investing.com Australia
Carisma Therapeutics reports data from its CAR-M therapy - TipRanks
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma - PR Newswire
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Malaysian Reserve
Carisma Therapeutics reports Q3 EPS (31c), consensus (26c) - TipRanks
Carisma Therapeutics Inc. Unveils Promising Pre-Clinical Data on Anti-Gpc3 in Vivo Car-M Therapy for Hepatocellular Carcinoma - Marketscreener.com
Carisma Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CARISMA Therapeutics Inc Reports Q3 2024 Revenue of $3.39M and G - GuruFocus.com
Carisma Therapeutics Welcomes Sohanya Cheng to Board of Directors - MSN
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024 - Citizentribune
Carisma to present new data on CAR-M therapy for hepatocellular carcinoma - TipRanks
Carisma Therapeutics (NASDAQ:CARM) Upgraded at EF Hutton Acquisition Co. I - Defense World
Carisma shares climb on EF Hutton Buy rating - Investing.com India
Carisma Therapeutics Appoints Sohanya Cheng to Board of Directors - citybiz
Carisma Therapeutics names Sohanya Cheng to board - Investing.com India
Carisma Therapeutics Announces Changes to its Board of Directors - Quantisnow
Carisma Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Carisma Therapeutics faces Nasdaq delisting over market value By Investing.com - Investing.com Australia
Carisma Therapeutics faces Nasdaq delisting over market value - Investing.com
Carisma Therapeutics to Showcase Cutting-Edge Cancer Research at SITC 2024 - MSN
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - Yahoo Finance
Carly Rae Jepsen is engaged! Canadian singer shares happy news on social media: 'Very engaged over here' - Yahoo Canada Shine On
Carly Rae Jepsen Flaunts Blue Engagement Ring with Grammy Winning Fiancé - 2paragraphs Buzz
CRDF (Cardiff Oncology Inc) has impressive results - US Post News
Berkley W R Corp Sells 451,295 Shares of Cartica Acquisition Corp (NASDAQ:CITE) - MarketBeat
Carly Rae Jepsen is a fiancée! Singer announces engagement to Grammy-winning producer - USA TODAY
Carly Rae Jepsen Engaged to Producer Cole MGN: See Her RingE! Online - E! NEWS
'Very engaged over here': Singer Carly Rae Jepsen announces her engagement to music producer Cole M.G.N. - 9Honey Celebrity
Investing in Aclaris Therapeutics Inc (ACRS) Is Getting More Attractive - Knox Daily
Surprise! Carly Rae Jepsen Is Engaged!!! - PerezHilton.com
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now - Benzinga
Carly Rae Jepsen announces engagement to boyfriend Cole MGN after two years of dating - Daily Mail
Carly Rae Jepsen Proclaims Herself ‘Very Engaged Over Here’ in Photoshoot Showing Off Ring From Fiancé Cole M.G.N. - Billboard
Carly Rae Jepsen Engaged to Producer Cole M.G.N. - AceShowbiz Media
Carly Rae Jepsen & Boyfriend Cole M.G.N. Are Engaged! - Just Jared
Cole M.G.N. Entertainment News, Photos, and Videos - Just Jared
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
Hancock Whitney Corp Has $737,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Where Are They Now? Carisma Therapeutics - Life Science Leader Magazine
Gabelli Funds LLC Has $120.74 Million Stake in Crane (NYSE:CR) - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) PT Lowered to $40.00 at B. Riley - Defense World
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
Selling Buzz: Accuray Inc [ARAY] SVP Chief Financial Officer Pervaiz Ali sells 8,404 shares of the company - Knox Daily
A company insider recently sold 833 shares of Apollo Commercial Real Estate Finance Inc [ARI]. Should You Sale? - Knox Daily
Catalyst Pharmaceuticals (NASDAQ:CPRX) Hits New 1-Year High at $21.10 - MarketBeat
Finanzdaten der Carisma Therapeutics Inc-Aktie (CARM)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):